A panelist discusses how intranasal epinephrine could revolutionize anaphylaxis management by overcoming barriers such as needle anxiety, delayed administration, and underuse—especially in pediatric and high-risk groups—through its needle-free, user-friendly design, rapid and effective drug delivery, longer shelf life, and temperature stability; coupled with the critical importance of early epinephrine use, updated guidelines, and shared decision-making, this innovation promises to improve patient outcomes by enhancing accessibility, caregiver confidence, and adherence while addressing practical issues like cost and education.
The content of this program has been supported by ARS Pharmaceuticals
EP. 1: An Overview of Anaphylaxis and the Importance of Speedy Delivery
July 7th 2025A panelist discusses how intranasal epinephrine could transform anaphylaxis management by improving accessibility, reducing treatment delays, and addressing underuse of epinephrine—especially in pediatric and high-risk populations—while emphasizing the need for better education and more user-friendly interventions to improve outcomes.
EP. 2: Epinephrine First: The Gold Standard in Anaphylaxis Treatment
July 7th 2025A panelist discusses the critical importance of early epinephrine administration in anaphylaxis for preventing severe outcomes, explaining its multireceptor action and lifesaving potential, while highlighting how intranasal delivery could enhance timely use and empower caregivers with faster, more accessible treatment options.
EP. 3: Needles, Nerves, and Knowledge: What Causes Delay to Epinephrine Treatment
July 7th 2025A panelist discusses how barriers such as cost, fear of injections, and lack of confidence delay epinephrine use in anaphylaxis and explains how intranasal delivery and updated guidelines may reduce hesitation and improve timely, effective treatment through better education and accessibility.
EP. 4: Bridging the Gaps in Treatment and Education of Epinephrine
July 7th 2025A panelist discusses how intranasal epinephrine represents a significant advance over traditional autoinjectors by eliminating needles, addressing user anxiety and real-world barriers, and potentially improving adherence and timely treatment in anaphylaxis emergencies.
EP. 5: Advancing Anaphylaxis Treatment: The Science Behind Intranasal Epinephrine
July 7th 2025A panelist discusses a newly approved intranasal epinephrine device for treating anaphylaxis in both children and adults, highlighting its needle-free delivery using a nasal spray with an absorption enhancer that ensures effective, safe drug uptake comparable to injections—even under nasal congestion—offering a promising alternative to traditional epinephrine autoinjectors.
EP. 6: The Clinical Safety and Practical Advantages to Intranasal Epinephrine
July 7th 2025A panelist discusses that the intranasal epinephrine device causes only mild, expected adverse effects such as nasal discomfort and headache, avoids injection-related risks, demonstrates rapid symptom improvement in pediatric food challenge studies, and offers practical advantages such as higher heat tolerance for storage and a longer shelf life compared with traditional autoinjectors.
EP. 7: Real-World Impact: Patient Cases of Anaphylaxis and Intranasal Epinephrine
July 7th 2025A panelist highlights how neffy, a needle-free, portable intranasal epinephrine device, addresses key unmet needs by reducing needle anxiety, enabling easy use by nonmedical caregivers, offering longer shelf life and temperature stability, and improving timely administration to prevent severe anaphylaxis outcomes, as demonstrated in clinical case examples.
EP. 8: From Insights to Action: Key Takeaways and Final Conclusions on Intranasal Epinephrine
July 7th 2025A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.